Deruxtecan
Based on 32 publication(s) in Google Scholar
Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.84%
- No. CAS: 1599440-13-7
- Fòrmula: C52H56FN9O13
- Peso molecular:1034.05
-
Almacenamiento:
-20°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Deruxtecan
More- Cancer Discov. 2026 Apr 2. [Abstract]
- Cancer Discov. 2025 Nov 10:10.1158/2159-8290.CD-25-0647. [Abstract]
- Adv Sci (Weinh). 2025 Oct 24:e06552. [Abstract]
- Adv Sci (Weinh). 2025 Apr;12(16):e2415577. [Abstract]
- J Control Release. 2024 Mar:367:779-790. [Abstract]
- Cancer Lett. 2025 Jan 9:217453. [Abstract]
- NPJ Precis Oncol. 2026 May 21. [Abstract]
- Int J Nanomedicine. 2025 Jan 17:20:723-739. [Abstract]
- Mol Cancer Ther. 2024 Nov 4;23(11):1639-1651. [Abstract]
- Mol Cancer Ther. 2023 Sep 5;22(9):1013-1027. [Abstract]
- Int J Mol Sci. 2025 Oct 29;26(21):10515. [Abstract]
- Biomolecules. 2024 Jan 15;14(1):106. [Abstract]
- J Drug Deliv Sci Technol. 2026 May 20;123:108493.
- Sci Rep. 2026 Apr 9;16(1):16106. [Abstract]
- Sci Rep. 2025 Mar 13;15(1):8735. [Abstract]
- Cancer Sci. 2024 Dec;115(12):3986-3996. [Abstract]
- Neoplasia. 2026 Mar 12:74:101295. [Abstract]
- Cancers (Basel). 2026 Jan 15;18(2):270. [Abstract]
- Pharm Res. 2026 Jun 16. [Abstract]
- AAPS J. 2025 Jun 4;27(4):106. [Abstract]
- AAPS J. 2022 May 27;24(4):70. [Abstract]
- bioRxiv. 2026 May 27.
- Res Sq. 2026 Apr 24:rs.3.rs-9194287. [Abstract]
- Patent. US20250255982A1.
- Cornell University. 2025.
- Patent. US20250222125A1.
- Patent. US20250163175A1.
- SSRN. 2024 Nov 5.
- Patent. US20240374749A1.
- Patent. US20240261424A1.
- Patent. US20240269315A1.
- Research Square Preprint. 2023 Dec 4.
Customer Validation & Images
-
WB
Ver todos los productos específicos de isoformas Drug-Linker Conjugates for ADC
More
Actividad biológica
|
Camptothecins |
Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 1599440-13-7
-
Appearance Solid
-
Peso molecular 1034.05
-
Fòrmula C52H56FN9O13
-
Color White to yellow
-
SMILES
O=C(C=CC1=O)N1CCCCCC(NCC(NCC(N[C@@H](CC2=CC=CC=C2)C(NCC(NCOCC(N[C@@H]3C4=C5C(C(N6C5)=CC([C@](O)(C(OC7)=O)CC)=C7C6=O)=NC8=CC(F)=C(C)C(CC3)=C48)=O)=O)=O)=O)=O)=O
-
Synonyms
MC-GGFG-DXD
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (32)
-
Journal Impact Factor
-
Most Recent
-
Cancer Discov
HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies. [Abstract]2026 Apr 2. PMID: 41925564 -
Cancer Discov
2025 Nov 10:10.1158/2159-8290.CD-25-0647. PMID: 41212147 -
Adv Sci (Weinh)
Interactions of Antibody Drug Conjugate Anti-Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy. [Abstract]2025 Oct 24:e06552. PMID: 41133986 -
Adv Sci (Weinh)
Reprogramming the Tumor Immune Microenvironment with ICAM-1-Targeted Antibody‒Drug Conjugates and B7-H3-CD3 Bispecific Antibodies. [Abstract]2025 Apr;12(16):e2415577. PMID: 39996528 -
J Control Release
In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment. [Abstract]2024 Mar:367:779-790. PMID: 38346501 -
Cancer Lett
Antibody-drug conjugates targeting SSEA-4 inhibits growth and migration of SSEA-4 positive breast cancer cells. [Abstract]2025 Jan 9:217453. PMID: 39798832 -
NPJ Precis Oncol
Development of a translational murine model for antibody-drug conjugate-induced interstitial lung disease. [Abstract]2026 May 21. PMID: 42168339 -
Int J Nanomedicine
Utility of 131I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models. [Abstract]2025 Jan 17:20:723-739. PMID: 39839455 -
Mol Cancer Ther
A DXd/TLR7-agonist dual-conjugate anti-HER2 ADC exerts robust anti-tumor activity through tumor cell killing and immune activation. [Abstract]2024 Nov 4;23(11):1639-1651. PMID: 39082754 -
Mol Cancer Ther
AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors. [Abstract]2023 Sep 5;22(9):1013-1027. PMID: 37302522 -
Int J Mol Sci
Zongertinib, a Novel HER2 Tyrosine Kinase Inhibitor, Maintains an Anticancer Activity for Trastuzumab Deruxtecan-Resistant Cancers Harboring HER2-Overexpression. [Abstract]2025 Oct 29;26(21):10515. PMID: 41226553 -
Biomolecules
An Anti-CD7 Antibody-Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leukemia (T-ALL). [Abstract]2024 Jan 15;14(1):106. PMID: 38254706 -
-
Sci Rep
Deruxtecan-based antibody-drug-conjugates induce senescence in HER2-positive breast cancer. [Abstract]2026 Apr 9;16(1):16106. PMID: 41957225 -
Sci Rep
2025 Mar 13;15(1):8735. PMID: 40082588 -
Cancer Sci
Anti-tissue factor antibody conjugated with monomethyl auristatin E or deruxtecan in pancreatic cancer models. [Abstract]2024 Dec;115(12):3986-3996. PMID: 39322584 -
Neoplasia
Rational payload selection enables high antitumoral efficacy of an anti-EGFR antibody-drug conjugate against ovarian tumors. [Abstract]2026 Mar 12:74:101295. PMID: 41825107 -
Cancers (Basel)
Poliovirus Receptor as a Potential Target in Gastric Signet-Ring Cell Carcinoma for Antibody-Drug Conjugate Development. [Abstract]2026 Jan 15;18(2):270. PMID: 41595191 -
Pharm Res
A Newly Designed Antibody-drug Conjugate Targeting B7-H3 Demonstrates Enhanced Therapeutic Efficacy Across a Spectrum of Cancers. [Abstract]2026 Jun 16. PMID: 42303884 -
AAPS J
2025 Jun 4;27(4):106. PMID: 40467988 -
AAPS J
Selection of Payloads for Antibody-Drug Conjugates Targeting Ubiquitously Expressed Tumor-Associated Antigens: a Case Study. [Abstract]2022 May 27;24(4):70. PMID: 35624189 -
-
Res Sq
Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory Properties. [Abstract]2026 Apr 24:rs.3.rs-9194287. PMID: 42078873 -
-
-
-
-
-
-
-
-
Solvente y solubilidad
DMF : 100 mg/mL (96.71 mM; Need ultrasonic)
DMSO : 73.33 mg/mL (70.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.75 mg/mL (1.69 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.75 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (17.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.75 mg/mL (1.69 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.75 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (17.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (274 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / DMF | 1 mM | 0.9671 mL | 4.8354 mL | 9.6707 mL | 24.1768 mL |
| 5 mM | 0.1934 mL | 0.9671 mL | 1.9341 mL | 4.8354 mL | |
| 10 mM | 0.0967 mL | 0.4835 mL | 0.9671 mL | 2.4177 mL | |
| 15 mM | 0.0645 mL | 0.3224 mL | 0.6447 mL | 1.6118 mL | |
| 20 mM | 0.0484 mL | 0.2418 mL | 0.4835 mL | 1.2088 mL | |
| 25 mM | 0.0387 mL | 0.1934 mL | 0.3868 mL | 0.9671 mL | |
| 30 mM | 0.0322 mL | 0.1612 mL | 0.3224 mL | 0.8059 mL | |
| 40 mM | 0.0242 mL | 0.1209 mL | 0.2418 mL | 0.6044 mL | |
| 50 mM | 0.0193 mL | 0.0967 mL | 0.1934 mL | 0.4835 mL | |
| 60 mM | 0.0161 mL | 0.0806 mL | 0.1612 mL | 0.4029 mL | |
| DMF | 80 mM | 0.0121 mL | 0.0604 mL | 0.1209 mL | 0.3022 mL |
Deruxtecan Related Classifications
HY-13631E Related Classifications
Powered by Bioz